Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis

Table 4 Overall survival and progression-free survival in different subgroups of mCRC patients

Patient subgroup	First-line regimen	n	Overall survival			Progression-free survival
			Median survival (months)	95% CI	p	Median survival (months)	95% CI	p
Stage I-III at diagnosis	FOLFOX	399	31.3	26.8-39.8	0.845	12.6	11.1-14.1	0.810
Stage I-III at diagnosis	XELOX	365	33.2	28.7-41.9	0.845	12.1	11.1-13.7	0.810
Stage IV at diagnosis	FOLFOX	819	25.3	22.7-29.5	0.311	11.1	10.5-12.1	0.370
Stage IV at diagnosis	XELOX	608	28.5	25.1-32.9	0.311	11.2	10.1-12.2	0.370
Without adjuvant chemotherapy	FOLFOX	927	25.2	22.5-28.8	0.212	11.1	10.5-11.9	0.414
Without adjuvant chemotherapy	XELOX	704	28.7	25.5-31.8	0.212	11.2	10.5-12.1	0.414
With adjuvant chemotherapy	FOLFOX	288	36.2	29.0-44.4	0.744	13.1	11.2-14.8	0.883
With adjuvant chemotherapy	XELOX	262	35.8	28.2-43.8	0.744	12.1	11.1-14.0	0.883
Wild type KRAS	FOLFOX	368	31.3	27.5-37.8	0.092	11.1	10.1-12.5	0.592
Wild type KRAS	XELOX	199	38.8	34.2-45.8	0.092	10.8	9.8-12.4	0.592
Mutant KRAS	FOLFOX	230	31.5	28.9-37.7	0.309	12.7	11.7-14.5	0.084
	XELOX	123	28.4	22.9-42.2		10.0	9.3-11.9

ISSN: 1471-2407